{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T04:04:13Z","timestamp":1745640253368,"version":"3.40.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>For many hematological malignancies (HMs) survival among older patients is compromised. We want to test the most up-to-date age-group-specific survival differences in five hematological malignancies, Hodgkin lymphoma (HL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and myeloproliferative diseases (MPD) in Sweden (SE) and compared these to Denmark, Finland and Norway. For analysis we apply a recently published metric for comparing and visualizing age-group-specific relative survival differences using data from the NORDCAN database between 1972 and 2021. Periodic changes in age-related deviation in SE survival showed increasing differences for AML and MM while for the other HMs the differences declined in the course of time. Country-specific differences were observed, for Finnish male CLL and female MPD deviations were larger than those for the other countries, both of which\u00a0were explained by the deviant survival of the oldest patients. Age-related deviations in 5-year survival increased for AML and MM for which survival improvements have been achieved through intense treatment regimens but these are not offered to old patients because of risk of complications. Paradoxically, improving overall survival in AML and MM has contributed to the widening of the age gaps. For the remaining HMs, age-related deviations declined with time as even old patients benefitted from the survival improvements; most notably female MPD and CLL patients had hardly any age gaps. Age disparities are an issue in hematological malignancies, and an intense search for novel treatments also includes old patients with an example of success as a novel drug venetoclax.<\/jats:p>","DOI":"10.1007\/s00277-025-06291-4","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T14:29:24Z","timestamp":1741271364000},"page":"1985-1993","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Visual presentation of age differences in relative survival of hematological neoplasms in Sweden and the neighboring countries"],"prefix":"10.1007","volume":"104","author":[{"given":"Kari","family":"Hemminki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frantisek","family":"Zitricky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"issue":"11","key":"6291_CR1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41408-022-00728-z","volume":"12","author":"K Hemminki","year":"2022","unstructured":"Hemminki K, Hemminki J, F\u00f6rsti A, Sud A (2022) Survival trends in hematological malignancies in the Nordic countries through 50 years. Blood Cancer J 12(11):150","journal-title":"Blood Cancer J"},{"issue":"4","key":"6291_CR2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41375-023-01852-w","volume":"37","author":"K Hemminki","year":"2023","unstructured":"Hemminki K, Hemminki J, F\u00f6rsti A, Sud A (2023) Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment. Leukemia 37(4):854\u2013863","journal-title":"Leukemia"},{"issue":"5","key":"6291_CR3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41408-020-0323-4","volume":"10","author":"D Pulte","year":"2020","unstructured":"Pulte D, Jansen L, Brenner H (2020) Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J 10(5):56","journal-title":"Blood Cancer J"},{"issue":"21","key":"6291_CR4","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","volume":"68","author":"VT DeVita Jr","year":"2008","unstructured":"DeVita VT Jr, Chu E (2008) A history of cancer chemotherapy. Cancer Res 68(21):8643\u20138653","journal-title":"Cancer Res"},{"issue":"8","key":"6291_CR5","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3390\/medicina55080414","volume":"55","author":"S Crisci","year":"2019","unstructured":"Crisci S, Amitrano F, Saggese M, Muto T, Sarno S, Mele S et al (2019) Overview of current targeted anti-cancer drugs for therapy in onco-hematology. Medicina (Kaunas) 55(8):414","journal-title":"Medicina (Kaunas)"},{"issue":"24","key":"6291_CR6","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.3390\/cancers15245765","volume":"15","author":"W Olejarz","year":"2023","unstructured":"Olejarz W, Basak G (2023) Emerging therapeutic targets and drug resistance mechanisms in immunotherapy of hematological malignancies. Cancers 15(24):5765","journal-title":"Cancers"},{"issue":"1","key":"6291_CR7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41392-023-01521-5","volume":"8","author":"L Tang","year":"2023","unstructured":"Tang L, Huang Z, Mei H, Hu Y (2023) Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduct Target Ther 8(1):306","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"6291_CR8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ncponc1186","volume":"5","author":"AM Evens","year":"2008","unstructured":"Evens AM, Hutchings M, Diehl V (2008) Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol 5(9):543\u2013556","journal-title":"Nat Clin Pract Oncol"},{"issue":"4","key":"6291_CR9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41571-018-0136-6","volume":"16","author":"CH Pui","year":"2019","unstructured":"Pui CH, Nichols KE, Yang JJ (2019) Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nat Rev Clin Oncol 16(4):227\u2013240","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"6291_CR10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41409-018-0239-9","volume":"54","author":"B Yang","year":"2019","unstructured":"Yang B, Yu R, Cai L, Bin G, Chen H, Zhang H et al (2019) Haploidentical versus matched donor stem cell transplantation for patients with hematological malignancies: a systemic review and meta-analysis. Bone Marrow Transplant 54(1):99\u2013122","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"6291_CR11","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/vaccines9060614","volume":"9","author":"M Khan","year":"2021","unstructured":"Khan M, Maker AV, Jain S (2021) The Evolution of Cancer Immunotherapy. Vaccines (Basel). 9(6):614","journal-title":"Vaccines (Basel)."},{"issue":"15","key":"6291_CR12","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.ejca.2015.08.003","volume":"51","author":"R De Angelis","year":"2015","unstructured":"De Angelis R, Minicozzi P, Sant M, Dal Maso L, Brewster DH, Osca-Gelis G et al (2015) Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000\u20132007: Results of EUROCARE-5 population-based study. Eur J Cancer 51(15):2254\u20132268","journal-title":"Eur J Cancer"},{"issue":"9","key":"6291_CR13","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","volume":"15","author":"M Sant","year":"2014","unstructured":"Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczek B et al (2014) Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol 15(9):931\u2013942","journal-title":"Lancet Oncol"},{"issue":"13","key":"6291_CR14","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/cncr.30003","volume":"122","author":"D Pulte","year":"2016","unstructured":"Pulte D, Jansen L, Castro FA, Brenner H (2016) Changes in the survival of older patients with hematologic malignancies in the early 21st century. Cancer 122(13):2031\u20132040","journal-title":"Cancer"},{"key":"6291_CR15","doi-asserted-by":"crossref","first-page":"100706","DOI":"10.1016\/j.blre.2020.100706","volume":"42","author":"RM Shallis","year":"2020","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM (2020) Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Rev 42:100706","journal-title":"Blood Rev"},{"issue":"2","key":"6291_CR16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/ejh.13707","volume":"108","author":"CH Blimark","year":"2022","unstructured":"Blimark CH, Vangsted AJ, Klausen TW, Gregersen H, Szabo AG, Hermansen E et al (2022) Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries. Eur J Haematol 108(2):99\u2013108","journal-title":"Eur J Haematol"},{"issue":"18","key":"6291_CR17","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1182\/blood.2019001728","volume":"134","author":"G Juliusson","year":"2019","unstructured":"Juliusson G, Hagberg O, Lazarevic VL, \u00d6lander E, Antunovic P, Cammenga J et al (2019) Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. Blood 134(18):1558\u20131561","journal-title":"Blood"},{"issue":"8","key":"6291_CR18","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1080\/10428194.2021.1893315","volume":"62","author":"TMH Naur","year":"2021","unstructured":"Naur TMH, Jakobsen LH, Roug AS, El-Galaly TC, Marcher CW, N\u00f8rgaard JM et al (2021) Treatment intensity and survival trends among real-world elderly AML patients diagnosed in the period 2001\u20132016: a Danish nationwide cohort study. Leuk Lymphoma 62(8):2014\u20132017","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"6291_CR19","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.105","volume":"6","author":"C da Cunha-Bang","year":"2016","unstructured":"da Cunha-Bang C, Simonsen J, Rostgaard K, Geisler C, Hjalgrim H, Niemann CU (2016) Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients. Blood Cancer J 6(11):e499","journal-title":"Blood Cancer J"},{"issue":"1","key":"6291_CR20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-024-01033-7","volume":"14","author":"K Hemminki","year":"2024","unstructured":"Hemminki K, Zitricky F, F\u00f6rsti A, Kontro M, Gjertsen BT, Severinsen MT et al (2024) Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century. Blood Cancer J 14(1):44","journal-title":"Blood Cancer J"},{"issue":"1","key":"6291_CR21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41408-024-01026-6","volume":"14","author":"K Hemminki","year":"2024","unstructured":"Hemminki K, Zitricky F, F\u00f6rsti A, Silvennoinen R, Vangsted A, Hansson M (2024) Large differencies in age-specific survival in multiple myeloma in the nordic countries. Blood Cancer J 14(1):43","journal-title":"Blood Cancer J"},{"issue":"11","key":"6291_CR22","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1016\/S2352-3026(21)00241-6","volume":"8","author":"R Cordoba","year":"2021","unstructured":"Cordoba R, Eyre TA, Klepin HD, Wildes TM, Goede V (2021) A comprehensive approach to therapy of haematological malignancies in older patients. Lancet Haematol 8(11):e840\u2013e852","journal-title":"Lancet Haematol"},{"issue":"5","key":"6291_CR23","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3109\/02841861003782017","volume":"49","author":"G Engholm","year":"2010","unstructured":"Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A et al (2010) NORDCAN\u2013a Nordic tool for cancer information, planning, quality control and research. Acta Oncol 49(5):725\u2013736","journal-title":"Acta Oncol"},{"key":"6291_CR24","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/0284186X.2017.1407039","volume":"57","author":"E Pukkala","year":"2018","unstructured":"Pukkala E, Engholm G, Hojsgaard Schmidt LK, Storm H, Khan S, Lambe M et al (2018) Nordic Cancer Registries - an overview of their procedures and data comparability. Acta Oncol 57:440\u2013455","journal-title":"Acta Oncol"},{"key":"6291_CR25","unstructured":"Lar\u00f8nningen SAG, Bray F, Engholm G, Ervik M, Gu\u00f0mundsd\u00f3ttir EM, Gulbrandsen J, Hansen HL, Hansen HM, Johannesen TB, Kristensen S, Kristiansen MF, Lam F, Laversanne M, Miettinen J, M\u00f8rch LS, \u00d3lafsd\u00f3ttir E, Pejicic S, Petterson D, Steig B\u00c1, Skog A, Tian H, Aagnes B, Storm HH (2023) NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic Countries, Version 9.3 (02.10.2023)"},{"issue":"1","key":"6291_CR26","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1186\/s12885-016-2967-9","volume":"16","author":"M Pohar Perme","year":"2016","unstructured":"Pohar Perme M, Est\u00e8ve J, Rachet B (2016) Analysing population-based cancer survival - settling the controversies. BMC Cancer 16(1):933","journal-title":"BMC Cancer"},{"key":"6291_CR27","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2024.102586","volume":"91","author":"F Zitricky","year":"2024","unstructured":"Zitricky F, Hemminki K (2024) A metric for comparison and visualization of age disparities in cancer survival. Cancer Epidemiol 91:102586","journal-title":"Cancer Epidemiol"},{"issue":"11","key":"6291_CR28","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","volume":"20","author":"M Arnold","year":"2019","unstructured":"Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM, Myklebust T et al (2019) Progress in cancer survival, mortality, and incidence in seven high-income countries 1995\u20132014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol 20(11):1493\u20131505","journal-title":"Lancet Oncol"},{"key":"6291_CR29","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ejca.2008.11.028","volume":"45","author":"A Quaglia","year":"2009","unstructured":"Quaglia A, Tavilla A, Shack L, Brenner H, Janssen-Heijnen M, Allemani C et al (2009) The cancer survival gap between elderly and middle-aged patients in Europe is widening. Eur J Cancer 45:1006\u20131016","journal-title":"Eur J Cancer"},{"issue":"11","key":"6291_CR30","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/ijc.34463","volume":"152","author":"DR Withrow","year":"2023","unstructured":"Withrow DR, Nicholson BD, Morris EJA, Wong ML, Pilleron S (2023) Age-related differences in cancer relative survival in the United States: a SEER-18 analysis. Int J Cancer 152(11):2283\u20132291","journal-title":"Int J Cancer"},{"issue":"2","key":"6291_CR31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/ijc.34705","volume":"154","author":"MS Schuurman","year":"2024","unstructured":"Schuurman MS, Lemmens V, Portielje JEA, van der Aa MA, Visser O, Dinmohamed AG (2024) The cancer burden in the oldest-old: increasing numbers and disparities-A nationwide study in the Netherlands, 1990 to 2019. Int J Cancer 154(2):261\u2013272","journal-title":"Int J Cancer"},{"issue":"1","key":"6291_CR32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","volume":"15","author":"R De Angelis","year":"2014","unstructured":"De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D et al (2014) Cancer survival in Europe 1999\u20132007 by country and age: results of EUROCARE\u20135-a population-based study. Lancet Oncol 15(1):23\u201334","journal-title":"Lancet Oncol"},{"issue":"7","key":"6291_CR33","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/ijc.33326","volume":"148","author":"S Pilleron","year":"2021","unstructured":"Pilleron S, Charvat H, Araghi M, Arnold M, Fidler-Benaoudia MM, Bardot A et al (2021) Age disparities in stage-specific colon cancer survival across seven countries: An International Cancer Benchmarking Partnership SURVMARK-2 population-based study. Int J Cancer 148(7):1575\u20131585","journal-title":"Int J Cancer"},{"issue":"1","key":"6291_CR34","doi-asserted-by":"crossref","first-page":"e000644","DOI":"10.1136\/bmjgast-2021-000644","volume":"8","author":"K Hemminki","year":"2021","unstructured":"Hemminki K, F\u00f6rsti A, Hemminki A (2021) Survival in colon and rectal cancers in Finland and Sweden through 50 years. BMJ Open Gastroenterol 8(1):e000644","journal-title":"BMJ Open Gastroenterol"},{"issue":"6","key":"6291_CR35","doi-asserted-by":"crossref","first-page":"e0253236","DOI":"10.1371\/journal.pone.0253236","volume":"16","author":"K Hemminki","year":"2021","unstructured":"Hemminki K, F\u00f6rsti A, Hemminki A, Ljungberg B, Hemminki O (2021) Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden. PLoS ONE 16(6):e0253236","journal-title":"PLoS ONE"},{"issue":"1","key":"6291_CR36","doi-asserted-by":"crossref","first-page":"e0261124","DOI":"10.1371\/journal.pone.0261124","volume":"17","author":"K Hemminki","year":"2022","unstructured":"Hemminki K, F\u00f6rsti A, Hemminki A, Ljungberg B, Hemminki O (2022) Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years. PLoS ONE 17(1):e0261124","journal-title":"PLoS ONE"},{"issue":"35","key":"6291_CR37","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1200\/JCO.20.00264","volume":"38","author":"GM Dores","year":"2020","unstructured":"Dores GM, Curtis RE, Dalal NH, Linet MS, Morton LM (2020) Cause-specific mortality following initial chemotherapy in a population-based cohort of patients with classical Hodgkin Lymphoma, 2000\u20132016. J Clin Oncol 38(35):4149\u20134162","journal-title":"J Clin Oncol"},{"issue":"12","key":"6291_CR38","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"issue":"Suppl 4","key":"6291_CR39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/annonc\/mdp141","volume":"20","author":"M Fey","year":"2009","unstructured":"Fey M, Dreyling M (2009) Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):100\u2013101","journal-title":"Ann Oncol"},{"key":"6291_CR40","unstructured":"Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D et al (2019) Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw: JNCCN 17(6):721\u201349"},{"issue":"12","key":"6291_CR41","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/ijc.33762","volume":"149","author":"K Hemminki","year":"2021","unstructured":"Hemminki K, F\u00f6rsti A, Houlston R, Sud A (2021) Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. Int J Cancer 149(12):1980\u20131996","journal-title":"Int J Cancer"},{"key":"6291_CR42","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.27138","volume":"99","author":"N Gangat","year":"2024","unstructured":"Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M et al (2024) Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol 99:193\u2013202","journal-title":"Am J Hematol"},{"issue":"19","key":"6291_CR43","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","volume":"388","author":"B Eichhorst","year":"2023","unstructured":"Eichhorst B, Niemann CU, Kater AP, F\u00fcrstenau M, von Tresckow J, Zhang C et al (2023) First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med 388(19):1739\u20131754","journal-title":"N Engl J Med"},{"issue":"3","key":"6291_CR44","first-page":"107815522312189","volume":"30","author":"WJ Khan","year":"2023","unstructured":"Khan WJ, Ali M, Hashim S, Nawaz H, Hashim SN, Safi D et al (2023) Use of venetoclax in t(11;14) positive relapsed\/refractory multiple myeloma: A systematic review. J Oncol Pharm Pract 30(3):10781552231219000","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"6291_CR45","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood.2023022535","volume":"143","author":"MS Raab","year":"2024","unstructured":"Raab MS (2024) Venetoclax in myeloma: to B, or not to B. Blood 143(1):4\u20135","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06291-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06291-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06291-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:11:03Z","timestamp":1745575863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06291-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6291"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06291-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Aggregated data from a publicly accessible database were used posing no ethical issues.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}